NIH Says Yes to Supps for Eyes

From eNewsletter 6/22/2022

DID YOU KNOW that the 2021-2022 flu shot was a complete dud? The CDC's Morbidity & Mortality Weekly Report states: "Overall, vaccine effectiveness against medically attended outpatient ARI associated with influenza A(H3N2) virus was 16%, which is considered not statistically significant. This analysis indicates that influenza vaccination did not reduce the risk for outpatient medically attended illness with influenza A(H3N2) viruses that predominated so far this season." Even more damning was this statistic: "Among participants with a positive influenza test result, 41% had received the 2021-22 seasonal influenza vaccine, compared with 50% of influenza test result-negative participants."

Announcements

Action Plan Update! Recent updates to our Action Plan Library Titles.

• Blood Sugar Balance

• Fast Mimicking Diet

• Heart Health

• Improve Your Mood

• Nutrition & Lifestyle for Cancer Prevention

• Optimal Pregnancy

• Salicylates

For NCI Well Connect paid members, it is free for download at Members Only Archives. For nonpaid members, they can be ordered a la carte at our shopsite (use the password: discount2018 to get past the Guest Area paywall).

Text Us We accept text messages. Type (847) 498-3422 and text away!

COVID-19 Vaccine Information View this document here.

Virus Prevention And Treatment Vaccines minimize COVID-19 related mortality and hospitalizations, but SARS-CoV-2 is here to stay. Moreover, it is not the only virus we fight. There are influenza (flu), norovirus (stomach flu), adenovirus (common cold), and four other coronaviruses (common cold), among others. Continue your immune support year-round. For more information, refer to our Prevent and Fight Viruses 2.0 Protocol.

COVID-19 Condition Monograph For those interested in conventional and integrative treatments for COVID-19 with over 250 references, this is our COVID-19 Condition Monograph.

Post-COVID Syndrome 2.0 The official diagnosis for post-COVID syndrome (PCS) are symptoms that last for 12 weeks or more. If you, a family member, friend, coworker, or neighbor is suffering from PCS, diligently following our Post-COVID Syndrome 2.0 Action Plan for purchase, or free to paid members here (must use the password), can bring measurable improvement.

Have a happy, healthy day! Steve and Bonnie Minsky

In Today's Issue...

• Well Connect Feature: Testosterone Deficiency*

• NIH Says Yes to Supps for Eyes

• June 20% OFF Sale Items

• Chiro Corner NEW!

• Pure Genomics

• Blog Briefs

• Well Connect Member Benefits

*Paid Member Access Only

NIH Says Yes to Supps for Eye Health

Steve: Let's keep the streak going! For the third consecutive week, a medical journal, in this case a National Institutes of Health sponsored study appearing in JAMA Ophthalmology, lauded the benefits of complementary and alternative therapies by publishing the following statement on their website: "NIH study confirms benefit of supplements for slowing age-related macular degeneration". The Age-Related Eye Disease Studies (AREDS and AREDS2) established that dietary supplements can slow progression of age-related macular degeneration (AMD), the most common cause of blindness in older Americans. In a new report, scientists analyzed 10 years of AREDS2 data. They show that the AREDS2 formula, which substituted antioxidants lutein and zeaxanthin for beta-carotene, is even more effective at reducing risk of AMD progression. The original AREDS study, launched in 1996, showed that a dietary supplement formulation (500 mg vitamin C, 400 international units vitamin E, 2 mg copper, 80 mg zinc, and 15 mg beta-carotene) could significantly slow the progression of AMD from moderate to late disease. In AREDS2, begun in 2006, researchers compared the beta-carotene formulation to one with 10 mg lutein and 2 mg zeaxanthin instead. At the end of the five-year AREDS2 study period in 2011, the researchers concluded that lutein and zeaxanthin reduced the risk of AMD progression by about 26%. In this new report, the researchers followed up with participants an additional five years. The group originally assigned to receive lutein/zeaxanthin had an additional 20% reduced risk of progression to late AMD, which comes out to a 46% risk reduction! The recommended dosage in this study is not for everyone. We suggest meeting first with a knowledgable health professional to assess all of your supplemental needs. But this is certainly quite exciting!